Avecho Biotechnology Limited (AVE.AX)
AUD 0.01
(25.0%)
AUD 0.01
(25.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.32 Million AUD | -336.06% |
| 2022 | -1.22 Million AUD | 61.46% |
| 2021 | -3.17 Million AUD | -85.81% |
| 2020 | -1.7 Million AUD | 45.19% |
| 2019 | -3.11 Million AUD | -47.47% |
| 2018 | -2.11 Million AUD | 27.17% |
| 2017 | -2.89 Million AUD | 52.42% |
| 2016 | -6.09 Million AUD | 50.86% |
| 2015 | -12.39 Million AUD | 40.06% |
| 2014 | -20.67 Million AUD | -134.38% |
| 2013 | -8.82 Million AUD | 47.83% |
| 2012 | -16.91 Million AUD | 37.81% |
| 2011 | -27.19 Million AUD | -892.55% |
| 2010 | -2.74 Million AUD | 74.79% |
| 2009 | -10.86 Million AUD | 15.73% |
| 2008 | -12.89 Million AUD | -20.35% |
| 2007 | -10.71 Million AUD | 25.72% |
| 2006 | -14.42 Million AUD | -9.37% |
| 2005 | -13.18 Million AUD | -82.62% |
| 2004 | -7.22 Million AUD | -212.4% |
| 2003 | -2.31 Million AUD | -5.27% |
| 2002 | -2.19 Million AUD | 32.32% |
| 2001 | -3.24 Million AUD | 23.33% |
| 2000 | -4.23 Million AUD | -89.26% |
| 1999 | -2.23 Million AUD | -1360.0% |
| 1998 | -153.15 Thousand AUD | -14430.55% |
| 1997 | -1054.00 AUD | 99.42% |
| 1996 | -183 Thousand AUD | -128.75% |
| 1995 | -80 Thousand AUD | 72.97% |
| 1994 | -296 Thousand AUD | -101.36% |
| 1993 | -147 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -4.7 Million AUD | 0.0% |
| 2023 FY | -5.32 Million AUD | -336.06% |
| 2023 Q2 | -2.65 Million AUD | 0.0% |
| 2023 Q4 | -5.32 Million AUD | 0.0% |
| 2022 Q2 | -3.07 Million AUD | 0.0% |
| 2022 FY | -1.22 Million AUD | 61.46% |
| 2022 Q4 | -1.22 Million AUD | 0.0% |
| 2021 Q4 | -3.17 Million AUD | 0.0% |
| 2021 FY | -3.17 Million AUD | -85.81% |
| 2021 Q2 | -4.62 Million AUD | 0.0% |
| 2020 Q2 | -2.49 Million AUD | 0.0% |
| 2020 FY | -1.7 Million AUD | 45.19% |
| 2020 Q4 | -1.7 Million AUD | 0.0% |
| 2019 Q4 | -3.11 Million AUD | 0.0% |
| 2019 FY | -3.11 Million AUD | -47.47% |
| 2019 Q2 | -4.63 Million AUD | 0.0% |
| 2018 Q2 | -3.26 Million AUD | 0.0% |
| 2018 FY | -2.11 Million AUD | 27.17% |
| 2018 Q4 | -2.11 Million AUD | 0.0% |
| 2017 Q4 | -2.89 Million AUD | 0.0% |
| 2017 FY | -2.89 Million AUD | 52.42% |
| 2017 Q2 | -4.03 Million AUD | 0.0% |
| 2016 Q2 | -9.91 Million AUD | 0.0% |
| 2016 Q4 | -6.09 Million AUD | 0.0% |
| 2016 FY | -6.09 Million AUD | 50.86% |
| 2015 FY | -12.39 Million AUD | 40.06% |
| 2015 Q2 | -15.83 Million AUD | 0.0% |
| 2015 Q4 | -12.39 Million AUD | 0.0% |
| 2014 FY | -20.67 Million AUD | -134.38% |
| 2014 Q2 | -7.64 Million AUD | 0.0% |
| 2014 Q4 | -20.67 Million AUD | 0.0% |
| 2013 Q2 | -14.09 Million AUD | 0.0% |
| 2013 FY | -8.82 Million AUD | 47.83% |
| 2013 Q4 | -8.82 Million AUD | 0.0% |
| 2012 Q4 | -16.91 Million AUD | 0.0% |
| 2012 FY | -16.91 Million AUD | 37.81% |
| 2011 FY | -27.19 Million AUD | -892.55% |
| 2011 Q4 | -27.19 Million AUD | 0.0% |
| 2010 Q4 | -2.74 Million AUD | 0.0% |
| 2010 FY | -2.74 Million AUD | 74.79% |
| 2009 Q4 | -10.86 Million AUD | 0.0% |
| 2009 FY | -10.86 Million AUD | 15.73% |
| 2008 FY | -12.89 Million AUD | -20.35% |
| 2008 Q4 | -12.89 Million AUD | 0.0% |
| 2007 Q4 | -10.71 Million AUD | 0.0% |
| 2007 FY | -10.71 Million AUD | 25.72% |
| 2006 Q4 | -14.42 Million AUD | 0.0% |
| 2006 FY | -14.42 Million AUD | -9.37% |
| 2005 FY | -13.18 Million AUD | -82.62% |
| 2005 Q4 | -13.18 Million AUD | 0.0% |
| 2004 Q4 | -7.22 Million AUD | 0.0% |
| 2004 FY | -7.22 Million AUD | -212.4% |
| 2003 FY | -2.31 Million AUD | -5.27% |
| 2003 Q4 | -2.31 Million AUD | 0.0% |
| 2002 FY | -2.19 Million AUD | 32.32% |
| 2002 Q4 | -2.19 Million AUD | 0.0% |
| 2001 Q4 | -3.24 Million AUD | 0.0% |
| 2001 FY | -3.24 Million AUD | 23.33% |
| 2000 FY | -4.23 Million AUD | -89.26% |
| 2000 Q4 | -4.23 Million AUD | 0.0% |
| 1999 Q4 | -2.23 Million AUD | 0.0% |
| 1999 FY | -2.23 Million AUD | -1360.0% |
| 1998 FY | -153.15 Thousand AUD | -14430.55% |
| 1998 Q4 | -153.15 Thousand AUD | 0.0% |
| 1997 Q4 | -1054.00 AUD | 0.0% |
| 1997 FY | -1054.00 AUD | 99.42% |
| 1996 FY | -183 Thousand AUD | -128.75% |
| 1995 FY | -80 Thousand AUD | 72.97% |
| 1994 FY | -296 Thousand AUD | -101.36% |
| 1993 FY | -147 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -530.551% |
| Acrux Limited | -1.45 Million AUD | -265.517% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 93.28% |
| BTC Health Limited | -2.02 Million AUD | -163.543% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -74.558% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 96.096% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 97.088% |
| Biome Australia Limited | -1.56 Million AUD | -241.005% |
| Hexima Limited | -2.22 Million AUD | -139.386% |
| Immutep Limited | -122.18 Million AUD | 95.639% |
| Memphasys Limited | 4.13 Million AUD | 228.87% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 68.824% |
| Noxopharm Limited | -2.31 Million AUD | -129.716% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 47.561% |
| Race Oncology Limited | -17.18 Million AUD | 68.996% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 71.31% |
| Starpharma Holdings Limited | -19.83 Million AUD | 73.128% |
| Tissue Repair Ltd | -16.44 Million AUD | 67.586% |
| Biotron Limited | -386.06 Thousand AUD | -1280.39% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 57.297% |
| CSL Limited | 15.76 Billion AUD | 100.034% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 71.801% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -442.634% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -651.065% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 205.169% |
| Patrys Limited | -2.24 Million AUD | -137.843% |
| Orthocell Limited | -19.92 Million AUD | 73.253% |
| Imugene Limited | -91.56 Million AUD | 94.18% |
| PYC Therapeutics Limited | -65.76 Million AUD | 91.896% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 15.728% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 14.119% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 58.085% |
| Nanollose Limited | -96.22 Thousand AUD | -5438.316% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 11.549% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -7.572% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -192.239% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -330.33% |
| Nyrada Inc. | -4.76 Million AUD | -11.739% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 94.963% |
| Dimerix Limited | -21.99 Million AUD | 75.767% |
| PharmAust Limited | -9.71 Million AUD | 45.139% |
| AnteoTech Limited | -5 Million AUD | -6.552% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 69.688% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -56.921% |
| Actinogen Medical Limited | -9.13 Million AUD | 41.64% |
| Immuron Limited | -11.48 Million AUD | 53.593% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 66.509% |